IL6 and COVID-19: TCZ is a recombinant humanized anti-IL-6 receptor monoclonal antibody thatinhibits the binding of IL-6 and soluble IL-6 receptors to membrane,blocking IL-6 signaling and thereby reducing inflammation.44 It is commonly used in the treatment of rheumatoid arthritis, andmost recently considered for use in adult patients, with an age range of52–71, hospitalized with severe COVID-19.44,49